新版药品管理实施条例发布：允许创新药分段生产，加速好药上市

Core Viewpoint - The revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" aims to enhance drug innovation, streamline approval processes, and strengthen regulatory oversight, effective from May 15, 2026 [1][3][4]. Group 1: Drug Development and Registration - The new regulations support drug development and innovation guided by clinical value, encouraging the creation of new drugs and their clinical promotion [1][4]. - A fast-track registration process for new drugs has been established, along with clear procedures for re-registration and mechanisms for converting prescription drugs to over-the-counter status [1][4]. - The regulations introduce market exclusivity periods for pediatric and rare disease medications, as well as data protection for drugs with novel chemical components [1][6]. Group 2: Drug Production Management - The regulations enforce stricter management of drug production, emphasizing the responsibilities of drug marketing authorization holders during contract manufacturing [1][4]. - Specific management requirements for the production and sale of traditional Chinese medicine (TCM) products have been clarified [1][4]. Group 3: Drug Distribution and Usage - The regulations enhance the management of online drug sales, holding third-party platforms accountable for the quality of drugs sold [1][8]. - Medical institutions are required to improve their pharmaceutical management to ensure drug quality during usage [1][4]. Group 4: Drug Safety Supervision - The regulations specify measures for drug safety supervision and inspection, detailing the process for quality checks and the rights of parties to request re-examinations of inspection results [2][4]. - Strict legal responsibilities for violations have been established to ensure compliance [2]. Group 5: Intellectual Property Protection - The revised regulations strengthen the protection of drug intellectual property, introducing a data protection system and market exclusivity periods for innovative drugs [6]. - Pediatric drugs are granted a market exclusivity period of up to 2 years, while rare disease drugs can receive up to 7 years of exclusivity [6]. Group 6: Online Drug Sales Regulation - The regulations clarify the responsibilities of online drug trading platforms, requiring them to establish dedicated management systems and ensure compliance with sales qualifications [8][9]. - The regulations also encourage the implementation of quality management standards for TCM production [8][9]. Group 7: Production Flexibility - The regulations allow for segmented contract manufacturing of drugs, which is particularly beneficial for innovative drugs requiring specialized production processes [10][11]. - A pilot program for segmented production will begin in 2024, focusing on innovative biological products and urgently needed clinical products [10][11].